Category: Health

A recent study suggests that vitamin B3, taken in specific doses, may significantly reduce the risk of certain skin cancers in veterans over a long-term period.

A new study published in JAMA Dermatology indicates that vitamin B3, also known as nicotinamide, may play a crucial role in preventing skin cancer. The research highlights a notable decrease in the risk of basal cell carcinoma and squamous cell carcinoma among veterans who consumed this vitamin over a 25-year period.

The study analyzed health data from more than 33,000 veterans, utilizing records from the Veterans Affairs (VA) system spanning from 1999 to 2024. Participants who took nicotinamide at a dosage of 500 mg twice daily were compared with similar individuals who did not take the supplement. Matching criteria included age, sex, race, history of skin cancer, and exposure to other treatments.

Additionally, the researchers took into account whether participants had specific health conditions, such as a history of organ transplants or chronic lymphocytic leukemia. Among the study group, 12,287 patients received oral vitamin B3 for more than 30 days, while 21,479 patients did not take the vitamin.

The findings revealed that those who consumed vitamin B3 experienced a lower incidence of skin cancers overall. Specifically, the risk of developing basal cell carcinoma and squamous cell carcinoma was reduced by approximately 14% in individuals who took the supplement.

The study also examined the recurrence rates of skin cancer. It was noted that patients who began taking nicotinamide immediately following their first skin cancer diagnosis had a remarkable 54% reduced risk of the disease returning. However, this benefit was less pronounced in individuals diagnosed with multiple skin cancers.

For patients with organ transplants, the overall risk did not show significant differences unless they started taking vitamin B3 early, which appeared to lower the risk of squamous cell carcinoma.

The researchers concluded that their results indicate a decreased risk of skin cancer among patients treated with nicotinamide, with the most substantial effects observed when treatment was initiated after the first skin cancer diagnosis.

In a recent podcast episode from JAMA Dermatology, co-researcher Dr. Lee Wheless of Vanderbilt University Medical Center discussed the implications of these findings. He expressed a shift in his perspective regarding the use of nicotinamide for skin cancer prevention.

Dr. Wheless noted that he would not recommend immediate nicotinamide use for someone newly diagnosed with skin cancer. However, he acknowledged the importance of early intervention. “If a patient has developed that field cancerization already, I really question — is this going to be as effective as if we had started before?” he stated.

He emphasized the need for proactive measures, stating, “I think this really pushes me to say we need to start now and not wait for you to have that sixth, seventh or more skin cancer before we start doing something preventive.”

The study’s findings may encourage healthcare providers to consider vitamin B3 as a preventive measure against skin cancer, particularly for high-risk populations such as veterans.

As research continues to explore the benefits of nicotinamide, it may pave the way for new guidelines in skin cancer prevention and treatment strategies.

Source: Original article

New research indicates that specially formulated eye drops may provide an effective alternative to reading glasses for individuals experiencing age-related vision loss.

As individuals age, many encounter presbyopia, a condition characterized by age-related farsightedness that complicates close-up tasks such as reading. Traditionally, reading glasses have been the go-to solution for this common issue. However, recent research suggests that a new option may soon be available.

Scientists have discovered that specially formulated eye drops could potentially restore near vision for a significant number of patients, offering a non-surgical and glasses-free approach to managing age-related vision loss. This study, which involved 766 participants primarily in their mid-50s, was presented on September 14 at the 43rd Congress of the European Society of Cataract and Refractive Surgeons held in Denmark.

Instead of relying on glasses, researchers administered eye drops containing pilocarpine, a medication that aids in adjusting the eye’s focus, combined with diclofenac, a mild anti-inflammatory intended to enhance patient comfort during treatment. Dr. Giovanna Benozzi, the director of the Center for Advanced Research for Presbyopia in Buenos Aires, Argentina, emphasized the importance of this research, citing a significant unmet medical need in managing presbyopia.

“Current solutions, such as reading glasses or surgical interventions, have limitations, including inconvenience, social discomfort, and potential risks or complications,” Dr. Benozzi stated in a press release.

Participants in the study were instructed to apply the eye drops twice daily—once in the morning and again approximately six hours later, with the option of a third dose if necessary. Their near vision was assessed using small-print eye charts over a two-year period.

Remarkably, within an hour of the initial dose, patients demonstrated a notable improvement in their ability to read lines on the near-vision chart. In the lowest concentration of the drops, nearly all participants could read at least two additional lines, while those using stronger formulations were able to read three or more lines. After one year of consistent use, over 80% of patients continued to experience improved near vision without the need for glasses, with many enjoying these benefits for well over a year.

Side effects reported were relatively minor. Approximately one-third of participants experienced brief dimming of vision, while a smaller group noted mild irritation or headaches. Importantly, none of the patients discontinued the use of the drops due to these temporary and manageable side effects.

Dr. Benozzi clarified that while this treatment is not intended to replace surgical options for those seeking a permanent solution, it does offer a non-invasive alternative that could alleviate the need for constant reliance on reading glasses. “This gives patients flexibility and could spare many from having to constantly reach for their reading glasses,” she added.

Despite the promising results, experts caution that further research is necessary before these eye drops can be widely adopted. The study was conducted at a single center, raising questions about the generalizability of the findings across diverse populations.

While pilocarpine has been utilized in various eye treatments for decades, concerns remain regarding the long-term daily use of the drops. Potential side effects, such as diminished night vision or, in rare instances, more serious retinal complications, warrant careful consideration. Additionally, extended use of diclofenac may pose risks to the ocular surface, an area that requires further investigation.

External researchers acknowledge the encouraging nature of the findings but emphasize the need for larger, multi-center clinical trials with extended follow-up periods to validate the results.

Source: Original article

A dangerous drug-resistant bacteria known as NDM-CRE is rapidly spreading across the U.S., posing significant treatment challenges and increasing the risk of severe illness and death.

A concerning rise in drug-resistant bacterial infections is currently being observed in the United States, with the Centers for Disease Control and Prevention (CDC) issuing warnings about the escalating threat posed by NDM-producing carbapenem-resistant Enterobacterales (NDM-CRE). This particular strain of bacteria is known for its resistance to most antibiotics, making it increasingly difficult for healthcare professionals to treat infections effectively.

The CDC’s laboratory tests indicate a dramatic increase in NDM-CRE infections, which are part of a larger group known as carbapenem-resistant Enterobacterales (CRE). These bacteria have shown a troubling ability to withstand some of the most potent antibiotics available today. The term “NDM” refers to an enzyme called New Delhi metallo-beta-lactamase, which contributes to this resistance.

In 2020, NDM-CRE was responsible for approximately 12,700 infections and 1,100 deaths in the U.S. The current surge in cases could lead to even higher numbers, as the CDC reports that NDM-CRE infections have increased by more than 460% between 2019 and 2023. These infections can manifest in various forms, including urinary tract infections, pneumonia, bloodstream infections, and wound infections. Due to their antibiotic resistance, NDM-CRE infections are notoriously difficult to treat and can sometimes be fatal.

One of the challenges in addressing NDM-CRE infections is their potential for misdiagnosis or oversight. The CDC notes that these infections have not been common in the U.S., which may lead healthcare providers to overlook them in their diagnoses. Danielle Rankin, an epidemiologist in the CDC’s Division of Healthcare Quality Promotion, emphasized the seriousness of the situation. “This sharp rise in NDM-CRE means we face a growing threat that limits our ability to treat some of the most serious bacterial infections,” she stated in a press release. “Selecting the right treatment has never been more complicated, so it is vitally important that healthcare providers have access to testing to help them select the proper targeted therapies.”

Dr. Marc Siegel, a senior medical analyst for Fox News, described the trend as “very concerning,” highlighting the high risk of severe illness or death associated with these infections. He attributed part of the problem to the overuse of antibiotics, which contributes to the global trend of increasing antibiotic resistance. “It’s partly due to overuse of antibiotics, and part of a worldwide trend that breeds more and more resistance,” he explained.

Treatment options for carbapenem-resistant infections include novel antibiotics such as ceftazidime-avibactam, meropenem-vaborbactam, plazomicin, and eravacycline. However, Dr. Siegel noted a significant issue: the lack of sufficient antibiotics available for treatment due to profitability concerns in the pharmaceutical industry.

Infectious disease expert David Perlin, Ph.D., who serves as the chief scientific officer and executive vice president at the Hackensack Meridian Center for Discovery and Innovation in New Jersey, expressed his concerns about the current state of drug resistance in America. Although he was not involved in the CDC’s study, he shared his insights with Fox News Digital. “This is one of the many drug resistance concerns right now for Americans — especially since we are seeing that surveillance is not keeping up with the evolution of the pathogens,” he remarked. “We can certainly do better, once we realize the stakes here.”

Perlin confirmed that NDM-CRE infections are serious and can be life-threatening. “They’re constantly adapting to their environment and can acquire a range of drug resistance mechanisms that make them difficult to treat,” he noted. He also pointed out that some strains carry special carbapenemase genes, which enable them to resist treatment with the most common class of antibiotics. This characteristic makes them particularly dangerous for patients with compromised immune systems.

To combat the threat posed by NDM-CRE, Perlin recommends that patients remain proactive in discussing any persistent infections with their healthcare providers. “Healthcare providers can, and must, do better to provide testing closer to the point of care, especially in emergency departments, so these infections can be identified rapidly for effective treatment and infection control,” he advised. He cautioned that these infections can spread easily in hospital, nursing home, and community settings.

Dr. Siegel echoed the importance of early diagnosis and sanitation in healthcare settings, particularly for immunocompromised patients, where the risk of rapid spread is heightened. “The key is sanitizing settings and early diagnosis,” he stated.

The alarming rise in NDM-CRE infections underscores the urgent need for improved surveillance, testing, and treatment options to combat this growing public health threat.

Source: Original article

The cancer medication leucovorin shows promise as a therapy for autism spectrum disorder, potentially enhancing communication skills in children, according to federal health officials.

Federal health officials recently highlighted the potential of leucovorin, a cancer medication, to serve as a therapy for autism spectrum disorder (ASD). During a press conference on autism-related topics, FDA Commissioner Marty Makary, National Institutes of Health (NIH) Director Jay Bhattacharya, and Centers for Medicare and Medicaid Services Administrator Mehmet Oz discussed research indicating that leucovorin may improve communication skills in some children with autism.

The U.S. Food and Drug Administration (FDA) is preparing to approve leucovorin as a treatment for speech-related deficits associated with ASD. This approval will involve updating the drug’s label to include treatment for cerebral folate deficiency, a condition linked to autism. Following this label update, state Medicaid programs will be able to cover leucovorin for autism treatment, as stated in a press release from the Department of Health and Human Services (HHS).

The NIH is also set to initiate new research initiatives aimed at examining the safety and effectiveness of leucovorin for children with autism. Preliminary studies suggest that the drug could help some non-verbal children develop the ability to speak.

Leucovorin, a prescription vitamin, is primarily used to treat cancer and anemia. It functions similarly to folic acid, aiding in the restoration of folate levels in patients who struggle to absorb or utilize it effectively. Katy Dubinsky, a New York pharmacist and CEO of Vitalize, a private supplement company, explained that leucovorin is FDA-approved to mitigate the toxic effects of high-dose methotrexate in cancer treatment and to prevent or treat certain types of anemia caused by folate deficiency.

While leucovorin is not currently prescribed for autism, some families have reported significant improvements in their children’s communication skills through its off-label use. Dr. Richard E. Frye, a behavioral child neurologist in Arizona, has conducted research on the drug as part of his exploration of experimental treatments for children with ASD. He noted that leucovorin is a special form of vitamin B9 that is water-soluble and does not accumulate in the body.

Dr. Frye emphasized that folates have been deemed safe for long-term use, which is why they are supplemented in food. He pointed out that the primary benefit of leucovorin for children with autism is its potential to enhance language skills, although it may also improve social functioning, reduce repetitive behaviors, and strengthen attention skills. “We do find that leucovorin helps a substantial number of children with autism,” he said, adding that language improvement is the most measurable outcome in clinical trials.

Dr. Marc Siegel, a clinical professor of medicine at NYU Langone Health and Fox News’ senior medical analyst, also discussed the drug’s positive effects. He explained that central folate deficiency, characterized by a lack of folate in the brain, can disrupt neurological function. Research has shown that a significant percentage of children with ASD have antibodies against folic receptor alpha in the brain. Leucovorin is converted to folate in the brain through a different pathway, which may explain its beneficial effects.

Although small studies have indicated that leucovorin can improve neurological function and communication skills in children with ASD, experts agree that larger studies are necessary to confirm these findings. The long history of leucovorin’s use in cancer treatment helps mitigate associated risks, according to Dr. Frye. “One of the advantages of using leucovorin is that it’s been used for decades to protect the body from the effects of chemotherapy, so we know what dose to use and any side effects it may produce,” he stated.

However, Dr. Frye cautioned that some children may experience hyperactivity or may not respond to leucovorin, necessitating alternative treatments. He stressed the importance of consulting with a medical professional when considering leucovorin for autism treatment. “Leucovorin is given at much higher doses than regular vitamins, so it’s very important to work with a doctor knowledgeable in how to prescribe it,” he advised.

While leucovorin is available at pharmacies, Dr. Frye noted that some children may require a compounded form due to sensitivities to certain additives in commercial products. He expressed hope that the FDA will approve leucovorin for autism, allowing it to be widely prescribed as one of the first treatments following diagnosis.

Dubinsky concurred, stating that physicians may prescribe the “widely used and well-tolerated drug” for autism treatment based on clinical judgment and emerging evidence. She emphasized that FDA approval would lend stronger medical backing, transforming leucovorin from an off-label option into a recognized treatment. This could lead to insurance coverage, standardized dosing guidelines, and greater acceptance within the medical community.

Dr. Siegel added that leucovorin is a “safe drug” and should be considered for broader use based on recent research findings. However, Dr. Frye cautioned that there is “no magic bullet” for autism, noting that many children benefit from a combination of treatments. “It is unlikely that leucovorin will be used alone — it must be used with behavioral and speech therapy,” he said, adding that leucovorin could enhance outcomes for these therapies.

Dr. Andy Shih, chief science officer of Autism Speaks, highlighted the individuality of each child’s experience with autism. He noted that while some small studies have explored leucovorin as a potential treatment, larger controlled clinical trials are essential to determine its efficacy and safety. He urged families to consult with their doctors before considering off-label treatments.

Dubinsky concluded that if larger studies confirm leucovorin’s effectiveness, it could become a more accessible treatment option for children with autism who may benefit from it.

Source: Original article

New research indicates that being underweight may pose a greater mortality risk than being overweight, challenging traditional views on body mass index (BMI) and health.

A significant new study from Aarhus University Hospital in Denmark has revealed that individuals who are underweight face a higher risk of death compared to those who are overweight or moderately obese. The research, which followed over 85,000 adults, suggests that the long-held assumptions surrounding body mass index (BMI) and health may need reevaluation.

According to the findings, people categorized as underweight were nearly three times more likely to die during the study period than those at the upper end of the normal BMI range. Even participants within the “healthy” BMI range but on the lower end exhibited an increased risk of early mortality.

In contrast, those who were overweight or moderately obese did not show higher death rates when compared to individuals with BMIs in the upper-normal range. This challenges the traditional view that excess weight is inherently dangerous, suggesting that being “fat but fit” may be a more accurate reflection of health than previously thought.

The researchers presented their findings at the annual meeting of the European Association for the Study of Diabetes (EASD) held in Vienna last week. The study highlights the importance of body fat distribution and underlying health conditions in determining overall health outcomes.

Dr. Sigrid Bjerge Gribsholt, the lead researcher, emphasized that both underweight and obesity represent significant global health challenges. Obesity is known to disrupt metabolic processes, weaken the immune system, and increase the risk of various diseases, including Type 2 diabetes, cardiovascular diseases, and several types of cancer. Conversely, being underweight is often associated with malnutrition, weakened immunity, and nutrient deficiencies.

Jens Meldgaard Bruun, another researcher involved in the study, pointed out that visceral fat—fat stored deep within the abdomen—can have detrimental effects on metabolic health. He explained that individuals with the same BMI can have vastly different health outcomes based on where their body fat is distributed. For instance, someone with a BMI of 35 who carries excess fat around their abdomen may be at risk for conditions like Type 2 diabetes or high blood pressure, while another person with the same BMI but with fat distributed around their hips and thighs may be healthier.

Bruun noted that treatment for obesity should be personalized, taking into account these factors and other health conditions when determining target weight. This approach could lead to more effective management of obesity and its associated health risks.

Dr. Akshaya Srikanth Bhagavathula, an epidemiologist at North Dakota State University who was not involved in the research, commented on the implications of the findings. He stated that they support other recent studies while challenging existing medical guidelines that assume health risks increase steadily with BMI. Bhagavathula explained that higher death rates in individuals with lower BMIs may stem from underlying illnesses that cause weight loss, making low weight appear more dangerous than it truly is.

He added that obesity often precedes serious health issues, according to the World Health Organization. In older adults, age-related muscle loss can increase vulnerability to falls and infections, while mild excess weight may provide a protective effect by serving as an energy reserve during illness. The healthy and active lifestyle in Denmark, characterized by widespread cycling, may also contribute to this protective effect.

Bhagavathula emphasized the need to consider BMI alongside other health measures, such as waist-to-height ratios, muscle mass, cholesterol levels, and blood sugar levels, as well as factors like sex and ethnicity. He argued that current health messaging often places excessive focus on weight loss, leading to shame and unnecessary medical interventions for individuals who are overweight but maintain normal bodily functions.

In light of these findings, Bhagavathula advocates for a shift in health messaging towards a nutrition-focused approach that emphasizes how the body processes food, alongside promoting physical activity and balanced eating, rather than relying solely on BMI as an indicator of health.

This research underscores the complexity of the relationship between body weight, health, and mortality, suggesting that a more nuanced understanding is necessary for effective public health strategies.

Source: Original article

Vaccination is the most effective method for preventing hepatitis B, a serious liver infection that can lead to acute or chronic complications.

Medical experts emphasize that vaccination is the best prevention method for hepatitis B, a liver infection that can manifest in both acute and chronic forms. This viral infection has no cure and may result in a range of serious complications.

The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and his advisory group are scheduled to meet this week to discuss and vote on various vaccine recommendations, including those for hepatitis B, COVID-19, and measles, mumps, and rubella.

Hepatitis B is recognized as a significant viral infection that causes inflammation in the liver and is the most prevalent liver infection globally, according to the Cleveland Clinic. The World Health Organization estimates that approximately 254 million people worldwide are currently living with this infection.

The infection can present as acute hepatitis B, which is typically brief, or as chronic hepatitis B, which can lead to severe complications such as cirrhosis (scarring of the liver) and liver failure. The virus is transmitted through exposure to infected bodily fluids, including blood, saliva, and other secretions. Common routes of transmission include unprotected sexual contact, sharing needles or syringes, and the use of contaminated medical instruments. Additionally, a pregnant woman can pass the virus to her newborn during childbirth, as noted by the Mayo Clinic.

While anyone can contract hepatitis B, certain individuals are at a higher risk. This includes those with sexually transmitted infections, individuals undergoing immunosuppressive treatments (such as chemotherapy), patients receiving dialysis, and those with other liver diseases.

Although the viral infection does not always present symptoms, some common signs include abdominal pain, fatigue, fever, joint pain, loss of appetite, nausea, vomiting, and weakness. Other symptoms indicative of liver disease may include dark-colored urine, light or clay-colored stool, jaundice (yellowing of the skin and eyes), and swelling due to fluid accumulation in the abdomen, arms, and legs.

A person remains contagious as long as the virus is active in their body. Acute hepatitis B can last for up to six months, while individuals with active chronic hepatitis B can remain contagious indefinitely. In contrast, those with inactive chronic hepatitis B have a lower risk of transmission.

Both acute and chronic forms of hepatitis B can lead to various complications, including acute and chronic liver failure, cirrhosis, hepatitis D, and liver cancer, according to health experts.

Diagnosis of hepatitis B typically involves blood tests, imaging tests such as elastography of the liver tissue, or a liver biopsy. Blood tests can determine whether the virus is active or inactive.

While there is no cure for hepatitis B, certain antiviral medications can help make the virus inactive. In chronic cases, these medications must be taken indefinitely. If the infection progresses to cancer, surgical options may include removing part of the liver or, in severe cases, a liver transplant.

Vaccination remains the most effective way to prevent hepatitis B infection. The Centers for Disease Control and Prevention (CDC) recommends hepatitis B vaccination for all infants, children under 19, adults aged 19 to 59, and individuals over 60 who have risk factors. Various hepatitis B vaccines are available, each requiring different dosing schedules.

The Cleveland Clinic advises individuals with hepatitis B to avoid alcohol, maintain a healthy diet, protect themselves from other liver infections, and seek support as needed. They note, “If tests show you have hepatitis B, you may wonder how the disease will change your life. You may worry about spreading the virus to others. The good news is there are medications that keep chronic hepatitis B from spreading. And there are steps you can take to protect your overall health and protect others.”

Source: Original article

Adults who consume cannabis are nearly four times more likely to develop type 2 diabetes than non-users, according to a new study analyzing medical records across the U.S. and Europe.

A recent study reveals that adults who use cannabis are at a significantly higher risk of developing type 2 diabetes compared to those who do not partake in the substance. Researchers, led by Dr. Ibrahim Kamel from the Boston Medical Center in Massachusetts, conducted an extensive analysis of medical records from 54 healthcare organizations across the United States and Europe using the TriNetX Research Network.

The study examined approximately 96,800 individuals with cannabis-related diagnoses, ranging from casual users to those with dependency issues. This group was compared to more than 4.16 million individuals who had no recorded history of drug use or chronic illness.

Over a five-year period, the findings indicated that 2.2% of cannabis users developed type 2 diabetes, in stark contrast to just 0.6% of non-users. Even after adjusting for various health risks, including high blood pressure, cholesterol levels, heart disease, and the use of other substances like alcohol or cocaine, marijuana users still exhibited a heightened risk of diabetes.

Experts suggest that the increased risk may be linked to the effects of marijuana on appetite, metabolism, and insulin resistance. Cannabis use is frequently associated with poor dietary habits, which could contribute to elevated blood sugar levels over time.

As marijuana becomes increasingly legalized and socially accepted, it is often viewed as a safer alternative to alcohol or tobacco. However, the research highlights that the long-term health risks associated with cannabis use may be more severe than many people realize.

“As cannabis becomes more widely available and socially accepted and legalized in various jurisdictions, it is essential to understand its potential health risks,” Kamel stated in a press release.

While the study provides valuable insights, the researchers acknowledged certain limitations. The retrospective design of the study means it examined existing patient records rather than tracking new cases over time, making it challenging to establish a direct causal relationship between marijuana use and diabetes.

Moreover, the risk levels may vary significantly between occasional users and those who consume cannabis daily. The researchers also noted the potential for bias, as the study relied on self-reported cannabis use, which could be inaccurate, especially in regions where marijuana use is illegal. Additionally, the study did not quantify the amount of cannabis used by participants.

Given these findings, physicians may need to engage in discussions with patients about their cannabis use to better assess their overall diabetes risk and determine whether metabolic monitoring is necessary. Kamel emphasized the importance of integrating diabetes risk awareness into treatment and counseling for substance-use disorders.

“These new insights from reliable, real-world evidence highlight the importance of integrating diabetes risk awareness into substance-use disorder treatment and counseling,” he added.

Fox News Digital reached out to various cannabis industry organizations for comment regarding the study’s findings.

Source: Original article

Scientists have developed a non-invasive MRI technique that measures brain iron levels, potentially identifying individuals at higher risk for Alzheimer’s disease years before symptoms manifest.

Researchers at Johns Hopkins University have unveiled a novel MRI technique that may serve as an early warning system for Alzheimer’s disease by measuring iron levels in the brain. This non-invasive method, known as quantitative susceptibility mapping (QSM), could help identify patients at a heightened risk of developing the disease long before any cognitive symptoms appear.

High levels of iron in the brain have been linked to increased brain toxins and neurodegeneration, which can lead to cognitive decline. This is particularly concerning when iron interacts with the abnormal amyloid and tau proteins, which are characteristic of Alzheimer’s pathology. The findings suggest that monitoring brain iron levels could provide crucial insights into an individual’s risk of developing mild cognitive impairment (MCI), a common precursor to Alzheimer’s dementia.

“QSM is an advanced MRI technique developed over the last decade to measure tissue magnetic susceptibility with good precision,” said Xu Li, the study’s senior author and an associate professor of radiology at Johns Hopkins University. “QSM can detect small differences in iron levels across different brain regions, providing a reliable and non-invasive way to map and quantify iron in patients, which is not possible with conventional MR approaches.”

In comparison to traditional imaging methods for Alzheimer’s diagnosis, such as PET scans, QSM MRI is not only non-invasive but also more affordable. This affordability could enhance accessibility for patients and healthcare providers alike, potentially allowing for earlier interventions.

The study, published in the journal *Radiology*, involved 158 cognitively unimpaired participants from a previous research project. After a follow-up period of seven and a half years, the researchers found that elevated iron levels in two critical brain regions were associated with a significantly higher risk of MCI. These regions, the entorhinal cortex and putamen, are closely linked to memory and learning.

“The key takeaway of our study is that higher brain iron levels, especially in some critical brain regions related to memory and learning, are linked to a two to four times higher risk of developing MCI and faster cognitive decline,” Li explained. “Such brain iron changes may be measured years before memory loss, when the participants are still cognitively normal.”

Li emphasized the importance of these findings, noting that the risk of cognitive impairment is even greater in individuals with elevated levels of amyloid pathologies. However, he acknowledged some limitations in the study, particularly the demographic composition of the participant group, which primarily consisted of White, highly educated individuals with a strong family history of Alzheimer’s disease.

If future studies with larger and more diverse populations confirm these results, it could pave the way for broader applications of QSM in clinical settings, particularly for patients at increased risk of dementia. “I think we should be hopeful,” Li said. “We can use this kind of tool to help identify patients at higher risk of developing Alzheimer’s disease and potentially guide early interventions as new treatments become available.”

Li also mentioned that while brain iron is associated with neurodegeneration, it plays an essential role in cognitive health and neurodevelopment, especially in younger individuals. Although iron chelation therapies aimed at reducing iron levels in the brain are currently being explored for Alzheimer’s treatment, their efficacy remains unclear, necessitating further research.

The researchers aim to enhance the standardization, speed, and accessibility of QSM technology in clinical practice, which could ultimately benefit many individuals at risk for Alzheimer’s disease.

Source: Original article

Cardiothoracic surgeon Dr. Jeremy London emphasizes the importance of a balanced diet for heart health, advocating for the 80/20 approach that prioritizes whole foods while limiting processed items and alcohol.

Heart disease remains the leading cause of death in the United States, accounting for one in five fatalities, according to the U.S. Centers for Disease Control and Prevention (CDC). As various lifestyle factors contribute to declining heart health, nutrition plays a crucial role, experts assert.

In a recent interview with Fox News Digital, cardiothoracic surgeon Dr. Jeremy London discussed the significance of nutrition in maintaining heart health. He noted that dietary choices can be a sensitive subject, as different diets may yield varying results for individuals.

Dr. London, based in Savannah, Georgia, advocates for a focus on general dietary guidelines, particularly emphasizing the consumption of whole foods while avoiding processed items. He believes that achieving a balance in nutrition is essential for heart health. “If I can eat whole foods 80% of the time, that’s a win for me,” he stated. “And I think that’s reasonable.”

Hydration is another critical aspect of heart health, according to Dr. London. He recommends increasing water intake while limiting alcohol consumption. “That being said, your body, your rules, as long as you know the facts,” he remarked. “Alcohol is a personal choice, but it’s really toxic to every cell in the body.”

Dr. London advises individuals to be mindful of their food choices, encouraging a focus on whole foods while considering the potential benefits of reducing or eliminating alcohol. This advice is particularly relevant for those with heart-related conditions, such as high cholesterol, who should limit their intake of saturated fats.

While eggs have historically been associated with high cholesterol, recent research suggests they can be a heart-healthy option. Dr. London described eggs as a “wonderful nutritional source,” but he emphasized the importance of moderation. “The dietary portion of the endogenous cholesterol (produced naturally inside the body) is maybe not as important as we had thought previously,” he explained. “There are people who are ‘hyper responders’ and should avoid those situations, but [otherwise], eggs in moderation are a great source of protein and certain vitamins and minerals that you can’t get elsewhere.”

For individuals with high cholesterol or other heart conditions, Dr. London recommends limiting refined flours and sugars, noting a direct correlation between blood glucose and triglyceride levels. He also highlighted the role of exercise in achieving better health outcomes.

The 80/20 diet approach, which encourages healthy eating 80% of the time while allowing for some indulgences, has gained support from health experts. A recent article reviewed by WebMD noted that this balanced approach can provide “more freedom” with the remaining 20% of dietary choices. The article states that this method can influence weight management, especially when it helps individuals reduce their intake of unhealthy foods and monitor their calorie consumption.

The U.S. Department of Agriculture’s dietary guidelines recommend filling half of your plate with fruits and vegetables, opting for whole grains, varying sources of lean protein, and including low-fat or fat-free dairy. Additionally, they advise limiting sugars, sodium, and saturated fats.

Individuals with specific health conditions, such as diabetes, are encouraged to consult their healthcare provider before adopting the 80/20 eating plan.

Source: Original article

A recent study suggests that sucralose, a common artificial sweetener, may diminish the effectiveness of cancer treatments, although supplementation could help mitigate these negative effects.

A new study has raised concerns about the impact of sucralose, a widely used artificial sweetener, on the effectiveness of cancer treatments. Researchers from the University of Pittsburgh and UPMC Hillman Cancer Center found that sucralose could interfere with immunotherapy in cancer patients.

The study involved 132 patients diagnosed with melanoma, a particularly aggressive form of skin cancer, and non-small cell lung cancer, the most prevalent type of lung cancer. All participants were undergoing treatment with anti-PD1 immunotherapy, either alone or in combination with chemotherapy. They completed dietary questionnaires that assessed their consumption of artificial sweeteners.

Findings indicated that patients who consumed high amounts of sucralose experienced a “worse response” to immunotherapy and had “poorer survival” rates compared to those who consumed lower levels of the sweetener. Senior author Diwakar Davar, an associate professor of medicine at the University of Pittsburgh and a medical oncologist at UPMC Hillman Cancer Center, noted, “We found that sucralose impeded the effectiveness of immunotherapies across a range of cancer types, stages, and treatment modalities.”

Published in the journal Cancer Discovery, the research highlights the potential implications of dietary choices on cancer treatment outcomes. The study’s authors suggest that there may be a need for targeted nutrient supplementation, such as prebiotics, for patients who consume high levels of sucralose.

Interestingly, the researchers also discovered that supplementation with the amino acid arginine could counteract the adverse effects of sucralose and enhance the effectiveness of immunotherapy. This was demonstrated in a separate study involving mice, where arginine supplementation improved immunotherapy outcomes.

Lead author Abby Overacre, an assistant professor in the Department of Immunology at the University of Pittsburgh and UPMC Hillman Cancer Center, emphasized the challenges faced by cancer patients regarding dietary changes. “It’s easy to say, ‘Stop drinking diet soda,’ but when patients are being treated for cancer, they are already dealing with enough, so asking them to drastically alter their diet may not be realistic,” she stated. “We need to meet patients where they are. That’s why it’s so exciting that arginine supplementation could be a simple approach to counteract the negative effects of sucralose on immunotherapy.”

The study found that sucralose altered the gut microbiome in a way that reduced levels of arginine, an amino acid crucial for T-cell function, which is vital for the effectiveness of immunotherapy drugs. Overacre explained, “When arginine levels were depleted due to sucralose-driven shifts in the microbiome, T cells couldn’t function properly. As a result, immunotherapy wasn’t as effective in mice that were fed sucralose.”

Looking ahead, the researchers plan to initiate a clinical trial to investigate the effects of arginine supplementation in human cancer patients. They also aim to explore how other sugar substitutes may impact the effectiveness of immunotherapy.

The study received support from the National Institutes of Health, the Damon Runyon Cancer Research Foundation, and Gateway for Cancer Research.

In response to the study, Carla Saunders, president of the Calorie Control Council, emphasized the importance of consulting healthcare professionals for guidance. “For people undergoing cancer treatment, all guidance should come from their healthcare team,” she stated. She also noted that the study has limitations, including its reliance on animal research and a small observational study in humans that utilized self-reported dietary data, which can be prone to inaccuracies. “While continued research is critical, scientific regulatory authorities worldwide, including the FDA, have repeatedly confirmed sucralose’s safety for decades,” she added.

As research continues, the implications of dietary choices on cancer treatment remain an important area of investigation.

Source: Original article

A recent study indicates that azelastine nasal spray can significantly reduce the risk of COVID-19 infection, offering a promising preventive measure against the virus.

A new study conducted by researchers at Saarland University in Germany has revealed that a nasal spray, azelastine, can substantially lower the risk of COVID-19 infection. The phase 2 clinical trial, published in JAMA Internal Medicine, demonstrated that the spray reduced infection rates from 6.7% in the placebo group to just 2.2% among participants using the nasal spray.

The study took place from March 2023 to July 2024 at Saarland University Hospital and involved 450 healthy adult participants. These individuals were randomly assigned to receive either the azelastine nasal spray or a placebo, administered three times daily over a 56-day period. To monitor infection rates, researchers conducted SARS-CoV-2 rapid antigen tests twice a week. Participants exhibiting symptoms but testing negative on antigen tests underwent multiple PCR tests for respiratory viruses.

Among the 227 participants who received the azelastine nasal spray, the results were promising. The confirmed COVID-19 infection rate was significantly lower at 2.2%, compared to 6.7% in the placebo group. The researchers also noted that the nasal spray extended the time before participants contracted the virus. Those using azelastine experienced fewer PCR-confirmed symptomatic infections and a reduced incidence of rhinovirus infections, which are commonly associated with the common cold.

“In this single-center trial, azelastine nasal spray was associated with reduced risk of SARS-CoV-2 respiratory infections,” the researchers stated in their findings.

Azelastine has been available over the counter as a treatment for hay fever and has previously been suggested to possess antiviral properties against COVID-19 and other respiratory viruses. Professor Robert Bals, the lead researcher and director of the Department of Internal Medicine at Saarland University Medical Center, emphasized the significance of the trial’s findings in a real-world context.

“Azelastine nasal spray could provide an additional, easily accessible prophylactic to complement existing protective measures, especially for vulnerable groups, during periods of high infection rates or before traveling,” he said.

The researchers highlighted the importance of conducting larger, multicenter trials to further investigate the efficacy of azelastine nasal spray as an on-demand preventive treatment. They also aim to explore its potential effectiveness against other respiratory pathogens.

As the world continues to navigate the challenges posed by COVID-19, this research offers a hopeful perspective on additional preventive measures that could help mitigate the virus’s spread.

Source: Original article

Two people have died from Vibrio vulnificus infections linked to contaminated Louisiana oysters, raising the total death toll to eleven across Louisiana and Florida.

Health officials have confirmed that two individuals died after consuming oysters contaminated with the flesh-eating bacterium Vibrio vulnificus. The cases were traced back to Louisiana-harvested oysters served in restaurants in both Louisiana and Florida. This outbreak has now resulted in a total of six deaths in Louisiana and five in Florida, according to the respective health departments of both states.

The Louisiana Department of Health issued a statement on July 31, urging residents to take precautions against vibriosis, the infection caused by Vibrio vulnificus. This bacterium is part of a broader group of Vibrio bacteria, which are typically found in coastal waters, as noted by the Centers for Disease Control and Prevention (CDC).

Dr. Andrew Handel, a pediatric infectious diseases specialist at Stony Brook Children’s Hospital in New York, explained that Vibrio has the potential to cause severe infections, including invasive soft tissue infections, commonly referred to as “necrotizing fasciitis” or “flesh-eating bacteria,” as well as bloodstream infections.

According to the CDC, most cases of vibriosis occur after individuals consume raw or undercooked shellfish, particularly oysters. In some instances, the bacteria can also enter the body through open wounds while swimming in contaminated waters.

Prior to the recent fatalities, health officials reported 17 cases of Vibrio vulnificus among Louisiana residents in 2025. All patients were hospitalized, and four of those cases resulted in death. Over the last decade, Louisiana has averaged seven reported cases of Vibrio vulnificus annually, with one death each year.

Jennifer Armentor, the molluscan shellfish program administrator at the Louisiana Department of Health, expressed concern about the current outbreak, stating, “It’s just prolific right now,” during a meeting with the Louisiana Oyster Task Force at the New Orleans Lakefront Airport.

Symptoms of vibriosis can vary depending on the type of infection. Dr. Handel previously noted that skin infections can escalate rapidly and become life-threatening. While healthy individuals typically experience mild symptoms, those who are immunocompromised or have chronic liver disease face heightened health risks.

If Vibrio vulnificus enters the bloodstream, it can lead to severe illness characterized by fever, chills, septic shock, and blistering skin lesions, according to Florida Health. Approximately half of these bloodstream infections can be fatal.

Severe cases may result in necrotizing fasciitis, where the tissue surrounding an open wound dies. Health officials diagnose the bacterial infection by testing cultures obtained from stool, wounds, or blood.

For mild infections, the CDC recommends increasing fluid intake to prevent dehydration. Those with severe or prolonged infections should receive antibiotics to improve survival rates. In cases of infected wounds, surgical intervention may be necessary to remove dead tissue.

According to the CDC, about one in five individuals infected with Vibrio vulnificus will die, sometimes within a day or two of the onset of illness. Dr. Handel advises, “To prevent Vibrio food poisoning, avoid eating raw shellfish, especially if you are immunocompromised or have chronic liver disease.”

He added that while Vibrio infections are rare, they should not be a major cause for alarm. “If you do eat shellfish, ensure it has not been sitting out for a long time and comes from a hygienic source,” he cautioned.

As health officials continue to monitor the situation, the public is urged to remain vigilant and informed about the risks associated with consuming raw or undercooked shellfish.

Source: Original article